IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY (IGAN) explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY (IGAN) trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY (IGAN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to slow kidney damage in IgA nephropathy
Disease control Not yet recruitingThis study is testing whether an experimental capsule called HS-10542 can help control IgA nephropathy, a kidney disease where protein leaks into urine. About 90 adults with confirmed IgA nephropathy will take either the drug or a placebo for 24 weeks to see if it safely reduces …
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug trial aims to slow silent kidney damage
Disease control Not yet recruitingThis study is testing whether an investigational drug called zigakibart can slow the progression of IgA nephropathy, a kidney disease. It will involve 32 adults who will receive the drug for two years while researchers check their kidney tissue and function. The main goal is to s…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC